Breadcrumb

RI-MUHC ANNUAL REPORT 2020

null Executive messages

MESSAGE FROM BRUCE MAZER

Bruce Mazer, MD, Executive Director and Chief Scientific Officer (Interim), RI-MUHC, October 2016–June 2020, and Indra Gupta, MD, Deputy Executive Director and Deputy Chief Scientific Officer (Interim), RI-MUHC, and Head of Child Health Research (Interim), MUHC
Bruce Mazer, MD, Executive Director and Chief Scientific Officer (Interim), RI-MUHC, October 2016–June 2020, and Indra Gupta, MD, Deputy Executive Director and Deputy Chief Scientific Officer (Interim), RI-MUHC, and Head of Child Health Research (Interim), MUHC

There is no doubt that 2019-2020 was a year filled with challenges and achievements. Our research community is unique: dedicated, creative, forward-thinking and innovative. Child or adult, every patient who inspires our work at the Research Institute of the McGill University Health Centre (RI-MUHC) is unique, too, and deserves to benefit from exciting new targeted therapies.

Whether it is for landmark public health studies, understanding the implications of a new disease-causing gene in a single patient or family, planning for a bold new Clinical Innovation Platform, or our robust response to the COVID-19 pandemic, we may take tremendous pride in the successes of the past year. In our community of RI-MUHC researchers, trainees and staff, MUHC clinicians and patients, and committed funding partners, we are all drivers of personalized medicine.

MESSAGE FROM INDRA GUPTA

As we adapt to the challenging constraints of the pandemic, science has prevailed at the speed of light with landmark pediatric studies in COVID-19 research and innovative therapies in mental health for our most vulnerable and youngest patients. Our pediatric research community quickly demonstrated strength in these and other areas requiring multidisciplinary collaboration. This would not have been possible without the invaluable partnership of the Montreal Children’s Hospital Foundation, whose support safeguards the continuity of our research advancement and shaping of future scientists in child health research.

My sincerest gratitude to Dr. Bruce Mazer, whose leadership over the last four years has established the RI-MUHC on the global centre stage, and whose extraordinary steering efforts have sustained the acceleration of pivotal research during these precarious times.

MESSAGE FROM MCGILL UNIVERSITY HEALTH CENTRE

Peter Kruyt, Chairman, and Pierre Gfeller, MD CM MBA, Board member and MUHC President and Executive Director
Peter Kruyt, Chairman, and Pierre Gfeller, MD CM MBA, Board member and MUHC President and Executive Director

We are pleased to recognize the accomplishments of the Research Institute of the McGill University Health Centre (RI-MUHC) in the context of this annual report, and to thank researchers, trainees, management and support staff alike for their curiosity, fervour and focus.

As a subsidiary of the MUHC, the success of the RI-MUHC is intertwined with that of the MUHC. Together, we eye the future to change the present. We pivot to adapt to new realities and anticipate other needs. This is why leadership and sustained support are critical. In that regard, we would like to express particular gratitude to Dr. Bruce Mazer as outgoing Interim Executive Director and Chief Scientific Officer. His enthusiastic and extended service has helped the RI-MUHC address opportunities and challenges over the last four years, including those related to personalized medicine and the COVID-19 pandemic. We would also like to express gratitude to the RI‑MUHC’s teams, partners, funders, and supporters for acting collaboratively with purpose to achieve common goals. We look forward to many more impressive achievements in the year ahead.

MESSAGE FROM MCGILL UNIVERSITY

David Eidelman, MD, CM, Vice-Principal (Health Affairs) and Dean, Faculty of Medicine and Health Sciences, and Martha Crago, MD, CM, Vice-Principal (Research and Innovation)
David Eidelman, MD, CM, Vice-Principal (Health Affairs) and Dean, Faculty of Medicine and Health Sciences, and Martha Crago, MD, CM, Vice-Principal (Research and Innovation)

COVID-19 has taught us that in the face of a global health crisis, collaboration is paramount. At the outset of the pandemic, many McGill and RI-MUHC scientists whose research was abruptly interrupted turned on a dime to collectively fight the novel virus.

Of course, collaboration between our institutions is not new. The pioneering genetic research conducted in RI-MUHC and McGill labs offered the earliest glimpses of where we were heading: personalized medicine, which hailed the next frontier in medical research. Today, genetic testing leads to targeted cancer regimens, which improve outcomes in ways the first oncologists could never have imagined. We now use personalized medicine to treat an increasingly broad array of cancers, as well as for cardiovascular disease, microbiome research and more.

We offer our RI-MUHC colleagues a heartfelt thank-you for their leadership and contributions in fighting the pandemic. Congratulations on the advances achieved this year, be they COVID19-related or in any of the other areas in which you excel.

BOARD OF DIRECTORS

Peter Kruyt, Chair
Louise Proulx, Interim Vice-Chair until Dec. 2019
Pierre Lortie, Treasurer
Cinzia Raponi, Secretary
Graham Bagnall
Mary-Anne Carignan
Martha Crago
David Eidelman
Pierre Gfeller
Bruce Mazer
Raymond Royer
Gloria Tannenbaum

CENTRE DIRECTORS

Jean Bourbeau, Centre for Innovative Medicine
Kaberi Dasgupta, Centre for Outcomes Research and Evaluation
Don van Meyel, Centre for Translational Biology

AUDIT/INVESTMENT COMMITTEE

Pierre Lortie, Chair
Cinzia Raponi, Secretary
Graham Bagnall
Mary-Anne Carignan
Peter Kruyt
Jaime Pimstone
Dawn Singerman
Bruce Mazer

MANAGEMENT COMMITTEE

Bruce Mazer, Chair
Jenny Koulis, Secretary
Shari Baum
Jean Bourbeau
Miguel Burnier
Kaberi Dasgupta
David Eidelman
Reza Farivar-Mohseni
Liane Feldman
Gerald Fried
Indra Gupta
Costas Karatzas
Ariane Marelli
James Martin
Cinzia Raponi
Marc Rodger
Michael Shevell
Don van Meyel
Simon Wing

RESEARCH PROGRAM COUNCIL

Simon Wing, Chair until Aug. 2019
Ariane Marelli, Chair since Sep. 2019
Basil Petrof, Vice-Chair
Jenny Koulis, Secretary
Jean Bourbeau
Miguel Burnier
Daniel Dufort
Kaberi Dasgupta
Reza Farivar-Mohseni
Liane Feldman
Gerald Fried
Indra Gupta
Ed Harvey
Kashif Khan*
Costas Karatzas
Virginia Lee
James Martin
Bruce Mazer
Peter Metrakos
Keith Murai
Kim Phan*
Constantin Polychronakos
José Luis Ramirez-GarciaLuna*
Cinzia Raponi
Marc Rodger
Erwin Schurr
Michael Shevell
Don van Meyel

Guests:
Associate program leaders
Desjardins Centre for Advanced Training representative
Research program managers
____________
*Trainee Council representatives

SCIENTIFIC ADVISORY COMMITTEE (2019)

Jim Woodgett, Chair
Director of Research, Lunenfeld-Tanenbaum Research Institute

Karen Antman
Provost, Boston University Medical Campus and Dean, School of Medicine

Michael Brudno
Director, Centre for Computational Medicine, SickKids Research Institute

Elliot Chaikof
Surgeon-in-Chief, Beth Israel Deaconess Medical Center, and Professor, Harvard Medical School

Albert Descoteaux
Director, PhD Program in Virology-Immunology of INRS–Institute Armand Frappier

Elizabeth Eisenhauer
Clinician Scientist, Kingston General Hospital Research Institute

Susan Marlin
President and CEO, Clinical Trials Ontario

Freda Miller
Senior Scientist, Neurosciences & Mental Health, SickKids Research Institute

Paula Rochon
Vice-President, Research, and Senior Scientist, Women’s College Hospital



NEXT READ